BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more
BridgeBio Pharma Inc (BBIO) - Total Liabilities
Latest total liabilities as of September 2025: $2.92 Billion USD
Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) has total liabilities worth $2.92 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BridgeBio Pharma Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how BridgeBio Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BridgeBio Pharma Inc Competitors by Total Liabilities
The table below lists competitors of BridgeBio Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gfl Environmental Holdings Inc
NYSE:GFL
|
USA | $8.29 Billion |
|
Swiss Re Ltd
PINK:SSREY
|
USA | $108.71 Billion |
|
Postal Savings Bank of China Co. Ltd
PINK:PSBKF
|
USA | $17.44 Trillion |
|
ABN AMRO Bank N.V
PINK:AAVMY
|
USA | $386.17 Billion |
|
Globe Life Inc
NYSE:GL
|
USA | $24.84 Billion |
|
Guardant Health Inc
NASDAQ:GH
|
USA | $2.11 Billion |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
China | CN¥10.10 Billion |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
China | CN¥35.35 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down BridgeBio Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BridgeBio Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BridgeBio Pharma Inc (2017–2024)
The table below shows the annual total liabilities of BridgeBio Pharma Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.38 Billion | +25.84% |
| 2023-12-31 | $1.89 Billion | +1.12% |
| 2022-12-31 | $1.87 Billion | -0.55% |
| 2021-12-31 | $1.88 Billion | +215.32% |
| 2020-12-31 | $595.70 Million | +282.59% |
| 2019-12-31 | $155.70 Million | -72.51% |
| 2018-12-31 | $566.44 Million | +270.88% |
| 2017-12-31 | $152.73 Million | -- |